Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 3Other hematologic neoplasm 1NET 1Lymphoid 1Genitourinary 1Endocrine 1

Conditions

Gastroenteropancreatic Neuroendocrine Tumors 1

Interventions

Everolimus 2lutetium Lu 177 dotatate 1Somatostatin 1Sirolimus 1Positron Emission Tomography Computed Tomography 1Oxaliplatin 1Leucovorin 1Injections 1Fluorouracil 1Bevacizumab 1Axitinib 1Al18F-NOTA-octreotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Sirolimus × NET × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡